Valuation: Roche Holding AG

Market Cap 312B 381B 341B 285B 537B 35,782B 554B 3,761B 1,500B 19,092B 1,429B 1,398B 60,273B P/E 2026 *
21x
P/E 2027 * 18.9x
Enterprise Value 324B 395B 354B 296B 557B 37,126B 574B 3,902B 1,556B 19,810B 1,482B 1,451B 62,537B EV / Sales 2026 *
5.12x
EV / Sales 2027 * 4.8x
Free-Float
88.78%
Yield 2026 *
2.57%
Yield 2027 * 2.63%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 384B
-0.79%-4.48%+44.44%+127.49% 1,216B
+1.43%+1.11%+47.73%+82.08% 656B
+1.07%-1.21%+32.99%+106.31% 509B
-0.36%-3.25%+47.17%+64.58% 384B
-0.14%-1.87%+71.05%+40.63% 362B
-0.78%-0.52%+30.57%+57.98% 311B
-0.80%-0.21%+8.54%+35.56% 293B
+0.03%-1.20%+45.89%+68.76% 249B
-0.41%-2.22%+35.24%+105.68% 208B
Average -0.21%-0.38%+40.40%+76.56% 465.31B
Weighted average by Cap. -0.16%-1.21%+42.20%+88.35%

Financials

2026 *2027 *
Net sales 63.27B 77.18B 69.23B 57.75B 109B 7,255B 112B 763B 304B 3,871B 290B 283B 12,221B 66.1B 80.64B 72.33B 60.34B 114B 7,580B 117B 797B 318B 4,045B 303B 296B 12,769B
Net income 14.99B 18.29B 16.4B 13.69B 25.79B 1,719B 26.6B 181B 72.06B 917B 68.65B 67.18B 2,896B 16.59B 20.24B 18.16B 15.15B 28.54B 1,903B 29.44B 200B 79.75B 1,015B 75.98B 74.35B 3,205B
Net Debt 11.72B 14.3B 12.83B 10.7B 20.16B 1,344B 20.8B 141B 56.34B 717B 53.68B 52.53B 2,265B 5.25B 6.41B 5.75B 4.79B 9.03B 602B 9.31B 63.29B 25.24B 321B 24.04B 23.53B 1,014B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Roche Holding AG